ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1826

Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis

Sandra Hermann1, Andriko Palmowski1, Bukrhard Muche2, Kay-Geert Hermann3, Edgar Wiebe1 and Frank Buttgereit4, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Charité University Hospital, CCM, Berlin, Germany, 3Charité - Universitätsmedizin Berlin, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

Meeting: ACR Convergence 2022

Keywords: gout, osteoporosis, rheumatoid arthritis, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone fractures in postmenopausal women. Rheumatoid arthritis (RA), as a chronic inflammatory disease, is a risk factor for fractures in both men and women. The role of uric acid in patients with RA is not yet clarified. Further, there may be different effects of uric acid on organ tissues such as the lungs, depending on the hormone status of women. We aimed at investigating the effect of uric acid level on bone mineral density and the development of osteoporosis in patients with RA and whether there is a difference between premenopausal and postmenopausal women with RA.

Methods: We utilized data from the Rh-GIOP (Glucocorticoid-Induced Osteoporosis in Patients with chronic inflammatory Rheumatic diseases) cohort, a prospective, monocentric observational study conducted at our department. All female patients with a diagnosis of RA were included in the analysis. For assessing the association between uric acid levels and lowest (minimum) T-scores measured at the lumbar spine, hip or femur, we used linear regression with adjustment for various confounders. An interaction term was included to evaluate differential associations in pre- and postmenopausal women.

Results: A total of 206 patients with RA, available dual X-ray absorptiometry (DXA) measurements, and serum uric acid levels were included in the analysis. Of those, 167 were women, and 165 had their menopausal status documented: 16 were premenopausal (age 40.32±7.85) and 149 postmenopausal (age 64.49±9.69), respectively. Postmenopausal patients had lower T-scores than non-menopausal patients. In the analysis of the whole sample, uric acid was not associated with T-scores (slope -0.08; p=0.43), but after inclusion of the interaction term, we found that uric acid was strongly negatively associated with T-scores in premenopausal women (slope -1.02; p=0.008, figure 1).

Conclusion: Uric acid appears to be negatively associated with bone mineral density in premenopausal but not in postmenopausal women with RA. This might be due to the different effect on the bone depending on the hormone status of women. Of note, the sample size of premenopausal women with RA was small. Therefore, these findings have to be proven in a larger cohort.

Supporting image 1

Figure 1. Scatterplot of minimum T-scores and uric acid in female rheumatoid arthritis patients stratified by menopausal status. Grey shadows surrounding the regression lines are the respective 95% confidence intervals.


Disclosures: S. Hermann, AbbVie; A. Palmowski, None; B. Muche, Amgen, Gilead, Galapagos, UCB and Stadapharm, Kyowa Kirin; K. Hermann, AbbVie, Merck/MSD, Pfizer, Novartis, BerlinFlame GmbH; E. Wiebe, Medac, Novartis; F. Buttgereit, Horizon Therapeutics, Roche, Abbvie, AstraZeneca, Gruenenthal, Mundipharma, Pfizer.

To cite this abstract in AMA style:

Hermann S, Palmowski A, Muche B, Hermann K, Wiebe E, Buttgereit F. Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-of-high-uric-acid-levels-with-low-bone-mineral-density-in-pre-but-not-post-menopausal-women-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-high-uric-acid-levels-with-low-bone-mineral-density-in-pre-but-not-post-menopausal-women-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology